• 1
    Bruix J. Liver cancer: Still a long way to go. Hepatology 2011;54:1-2.
  • 2
    Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011;53:1020-1022.
  • 3
    Parisi G. Should a radiological diagnosis of hepatocellular carcinoma be routinely confirmed by a biopsy? Yes. Eur J Intern Med 2012;23:34-6.
  • 4
    Schirmacher P, Bedossa P, Roskams T, Tiniakos DG, Brunt EM, Zucman-Rossi J, et al. Fighting the bushfire in HCC trials. J Hepatol 2011;55:276-277.
  • 5
    Roncalli M, Park YN, Di Tommaso L. Histopathological classification of hepatocellular carcinoma. Dig Liver Dis 2010;42( suppl 3):S228-S234.
  • 6
    Park YN, Kojiro M, Di Tommaso L, Dhillon AP, Kondo F, Nakano M, et al. Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules. Cancer 2007;109:915-923.
  • 7
    Lennerz JK, Chapman WC, Brunt EM. Keratin 19 epithelial patterns in cirrhotic stroma parallel hepatocarcinogenesis. Am J Pathol 2011;179:1015-1029.
  • 8
    Bedossa P, Paradis V. Hepatocellular carcinoma. In: Saxena R, ed.Practical Hepatic Pathology: A Diagnostic Approach.St. Louis, MO:W.B. Saunders;2011:489-501.
  • 9
    Theise ND, Curado MP, Franceschi S, Hytiroglou P, Kudo M, Park YN, et al. Hepatocellular carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds.WHO Classification of Tumours of the Digestive System. 4th ed.Lyon, France:International Agency for Research on Cancer;2010:205-216.
  • 10
    Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005;25:133-142.
  • 11
    Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis 2010;30:17-25.
  • 12
    Park YN. Update on precursor and early lesions of hepatocellular carcinomas. Arch Pathol Lab Med 2011;135:704-715.
  • 13
    Bioulac-Sage P, Cubel G, Balabaud C, Zucman-Rossi J. Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers. Semin Liver Dis 2011;31:91-103.
  • 14
    Quaglia A, Jutand MA, Dhillon A, Godfrey A, Togni R, Bioulac-Sage P, et al. Classification tool for the systematic histological assessment of hepatocellular carcinoma, macroregenerative nodules, and dysplastic nodules in cirrhotic liver. World J Gastroenterol 2005;11:6262-6268.
  • 15
    Di Tommaso L, Franchi G, Park YN, Fiamengo B, Destro A, Morenghi E, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007;45:725-734.
  • 16
    Longerich T, Haller MT, Mogler C, Aulmann S, Lohmann V, Schirmacher P, et al. Annexin A2 as a differential diagnostic marker of hepatocellular tumors. Pathol Res Pract 2011;207:8-14.
  • 17
    Di Tommaso L, Destro A, Seok JY, Balladore E, Terracciano L, Sangiovanni A, et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 2009;50:746-754.